Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.690
-0.070 (-3.98%)
Jul 29, 2026, 2:01 PM EDT - Market open
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
96.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 55.54M |
| Verrica Pharmaceuticals | 37.16M |
| ImmuCell | 29.93M |
| Pelthos Therapeutics | 27.70M |
| Coya Therapeutics | 7.94M |
| Rani Therapeutics Holdings | 3.17M |
BDTX News
- 4 weeks ago - Black Diamond Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Transcript: Study result - Transcripts
- 2 months ago - Black Diamond Therapeutics Press release: Study result - Filings
- 2 months ago - Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - GlobeNewsWire